226 related articles for article (PubMed ID: 22149552)
1. Meningococcal quadrivalent (serogroups A, C, W135, and Y) conjugate vaccine (Menveo(®)): profile report.
Deeks ED
Paediatr Drugs; 2012 Feb; 14(1):63-5. PubMed ID: 22149552
[No Abstract] [Full Text] [Related]
2. Meningococcal group A, C, Y and W-135 conjugate vaccine.
Harrison LH; Mohan N; Kirkpatrick P
Nat Rev Drug Discov; 2010 Jun; 9(6):429-30. PubMed ID: 20514064
[TBL] [Abstract][Full Text] [Related]
3. Quadrivalent meningococcal conjugate vaccines.
Pace D; Pollard AJ; Messonier NE
Vaccine; 2009 Jun; 27 Suppl 2():B30-41. PubMed ID: 19477560
[TBL] [Abstract][Full Text] [Related]
4. Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients.
Wyplosz B; Derradji O; Hong E; François H; Durrbach A; Duclos-Vallée JC; Samuel D; Escaut L; Launay O; Vittecoq D; Taha MK
Transpl Infect Dis; 2015 Apr; 17(2):322-7. PubMed ID: 25645691
[TBL] [Abstract][Full Text] [Related]
5. Immunisation update: Meningococcal B and ACWY vaccines.
Davidson GT; Heaton PA; Paul SP
J Fam Health; 2015; 25(6):22-5. PubMed ID: 26749934
[No Abstract] [Full Text] [Related]
6. Assignment of Neisseria meningitidis serogroups A, C, W135, and Y anticapsular total immunoglobulin G (IgG), IgG1, and IgG2 concentrations to reference sera.
Joseph H; Balmer P; Bybel M; Papa T; Ryall R; Borrow R
Clin Diagn Lab Immunol; 2004 Jan; 11(1):1-5. PubMed ID: 14715537
[TBL] [Abstract][Full Text] [Related]
7. [Meningococcal vaccines: from polysaccharide to conjugate vaccines].
Cohen R; Levy C
Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368
[TBL] [Abstract][Full Text] [Related]
8. New rapid diagnostic tests for Neisseria meningitidis serogroups A, W135, C, and Y.
Chanteau S; Dartevelle S; Mahamane AE; Djibo S; Boisier P; Nato F
PLoS Med; 2006 Sep; 3(9):e337. PubMed ID: 16953658
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT.
Findlow H; Borrow R
Adv Ther; 2013 May; 30(5):431-58. PubMed ID: 23712402
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
[TBL] [Abstract][Full Text] [Related]
11. Meningococcal serogroup A, C, W, and Y serum bactericidal antibody profiles in Hajj pilgrims.
Memish ZA; Yezli S; Almasri M; Assiri A; Turkestani A; Findlow H; Bai X; Borrow R
Int J Infect Dis; 2014 Nov; 28():171-5. PubMed ID: 25307887
[TBL] [Abstract][Full Text] [Related]
12. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
Pace D
Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
[TBL] [Abstract][Full Text] [Related]
13. An Update on Meningococcal Vaccination.
Garland JM
R I Med J (2013); 2020 Aug; 103(6):41-43. PubMed ID: 32752565
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia.
Ilyina N; Kharit S; Namazova-Baranova L; Asatryan A; Benashvili M; Tkhostova E; Bhusal C; Arora AK
Hum Vaccin Immunother; 2014; 10(8):2471-81. PubMed ID: 25424958
[TBL] [Abstract][Full Text] [Related]
15. Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source.
Gill CJ; Ram S; Welsch JA; Detora L; Anemona A
Vaccine; 2011 Dec; 30(1):29-34. PubMed ID: 22075087
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of a Booster Dose of Quadrivalent Meningococcal Conjugate Vaccine in Previously Immunized HIV-Infected Children and Youth.
Warshaw MG; Siberry GK; Williams P; Decker MD; Jean-Philippe P; Lujan-Zilbermann J
J Pediatric Infect Dis Soc; 2017 Sep; 6(3):e69-e74. PubMed ID: 28339668
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children.
Siberry GK; Warshaw MG; Williams PL; Spector SA; Decker MD; Jean-Philippe P; Yogev R; Heckman BE; Manzella A; Roa J; Nachman S; Lujan-Zilbermann J;
Pediatr Infect Dis J; 2012 Jan; 31(1):47-52. PubMed ID: 21987006
[TBL] [Abstract][Full Text] [Related]
18. Expanding prevention of invasive meningococcal disease.
Pelton SI; Gilmet GP
Expert Rev Vaccines; 2009 Jun; 8(6):717-27. PubMed ID: 19485753
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.
Siberry GK; Williams PL; Lujan-Zilbermann J; Warshaw MG; Spector SA; Decker MD; Heckman BE; Demske EF; Read JS; Jean-Philippe P; Kabat W; Nachman S;
Pediatr Infect Dis J; 2010 May; 29(5):391-6. PubMed ID: 20431379
[TBL] [Abstract][Full Text] [Related]
20. Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005.
Ceyhan M; Yildirim I; Balmer P; Riley C; Laher G; Andrews N; Borrow R; Kurt N; Turgut M; Aydogan A; Ecevit C; Uysal G; Schultze V
Vaccine; 2007 Oct; 25(41):7233-7. PubMed ID: 17707957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]